Navigation Links
Science May Banish Bad Hair Days

Super close-up views of how strands interact could be key, researchers say

MONDAY, Aug. 18 (HealthDay News) -- Whether it's frizzy or flyaway, nearly everyone puts up with an unruly head of hair from time to time. Now scientists have trained their microscopes on hair to find out why it misbehaves -- and how to tame it.

In a new study, said to be the first of its kind, German researchers say they've gotten extreme-close-up views of how hair fibers interact. Their insights could lead to products that banish bad hair days for good, they say.

"At the moment, it is not known why hair feels good," explained study co-author Eva Max, a doctoral student in chemistry at the University of Bayreuth in Germany. That, in turn, makes it difficult to scientifically study hair care products, which make up a $60 billion industry worldwide.

In the new study, Max and colleagues explored the workings of hair with an atomic-force microscope and samples of Caucasian female hair. The study authors were scheduled to present their findings Aug. 17 at the American Chemical Society's national meeting, in Philadelphia.

According to the team, damage to hair causes scaly projections to protrude from hair fibers. These projections create friction with other fibers and make hair feel rough to the touch and hard to comb.

The researchers also found that electrical charges build up on hair, causing friction.

The next step is to figure out what happens to the hair when it's exposed to hair-care products such as shampoo and conditioner.

"There are several changes that take place at the same time when hair is exposed to hair care products, and it will help greatly to understand which of those changes is crucial for optimizing hair care," Max said. "If, for example, it would turn out that there is an optimum friction between single hairs for pleasant (touch), the molecular composition of hair-care products can be optimized to achieve this friction."

Steven Shiel, who studies hair at Proctor & Gamble, said the German research could help shed more light on how hair fibers interact and lead to better hair care products. "Those invisible-to-the-eye changes have a great impact on how the ingredients in the products affect the hair," he said.

Hair styling products have become more sophisticated in recent years, and this has much to do with science, said Shiel, an associate director with P&G Beauty.

"A lot of this is based on this fundamental understanding of hair's underlying structure and properties," he said. "Fundamentally understanding the hair structure is really important in terms of developing products that really deliver."

More information

Learn about hair loss and disease from the National Institutes of Health.

SOURCES: Eva Max, doctoral student, University of Bayreuth, Germany; Steven Shiel, Ph.D., associate director, Proctor & Gamble Beauty, Cincinnati; Aug. 17, 2008, American Chemical Society National Meeting, Philadelphia

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
2. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
3. Edwards Lifesciences to Present at the Bear Stearns 20th Annual Healthcare Conference
4. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
5. HealthFitness CEO Supports Move Toward Cultural Shift, and Science-Based Health Management Programming
6. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
7. John B. Buse, MD, PhD of Chapel Hill, NC, Elected American Diabetes Association President, Medicine & Science
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. SAMHSA Announces First Science and Service Award Winners
10. Novavax CEO to Present at the 2007 UBS Global Life Sciences Conference
11. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
Related Image:
Science May Banish Bad Hair Days
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... non-traumatic limb amputations in the United States. Podiatrists are well aware that psychology-based ... adopt therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic foot. ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the ... is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic ... the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President North America. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, the leader ... in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the ... finalist in the category of Digital Solutions for its innovative, industry-leading product, Alme ...
(Date:12/1/2015)... ... 2015 , ... TCS Healthcare Technologies (TCS), a leading provider ... is pleased to announce that VIP Care Services, a Caprock Health Group affiliate ... Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY Complete ...
(Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... BOSTON , December 1, 2015 Russia ... phase III clinical trials. 70% of new drugs registered in ... trials in Russia . --> Russia has ... trials. 70% of new drugs registered in Europe ... . --> Russia has always been ...
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. ... treatment of chronic pain, announced today that the company will ... be held December 1-3 at the Luxe Sunset Boulevard Hotel ... Traversa , CEO of Relmada Therapeutics, will present on Thursday, ... Time). . Please register at least 10 ...
(Date:12/1/2015)...   MabVax Therapeutics Holdings, Inc . (OTCQB: MBVX), ... filed an Investigational New Drug Application (IND) with the ... lead fully human antibody product HuMab 5B1 as a ... initiate the Phase I clinical trial early in 2016. ... The planned Phase I trial will evaluate the safety, ...
Breaking Medicine Technology: